PhaseBio Pharmaceuticals Inc

PhaseBio is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies to treat cardiovascular diseases. Our lead product candidate is bentracimab (PB2452), a novel reversal agent for the antiplatelet drug ticagrelor, and our second product candidate is PB6440, a highly selective aldosterone synthase inhibitor in development for treatment resistant hypertension and potentially other cardio-renal indications.

Our ELP platform technology is a growth engine for additional medicines for cardiovascular diseases. It offers the benefits of extended half-life, enhanced usability and simple manufacturing.


PLATFORM
Our ELP platform technology is a growth engine for additional medicines for cardiovascular diseases. It offers the benefits of extended half-life, enhanced usability and simple manufacturing.

ELP TECHNOLOGY
Our proprietary technology platform is based on recombinant biopolymers called elastin-like polypeptides (ELPs), which comprise individual building blocks derived from a five-amino acid repeat motif found in the human protein elastin. This five-amino acid motif is repeated multiple times to form the ELP biopolymer.

Our ELP technology extends the circulating half-life of proteins and peptides and also provides a sustained-release mechanism, resulting in exposure of active molecules for periods of a week or longer from a single subcutaneous injection.

Our strategy is to apply our ELP technology to proteins and peptides with well-characterized therapeutic activities but suboptimal half-lives to improve their pharmacokinetics, enable their use as pharmaceutical products and allow for more convenient dosing regimens.